- Home
- CHRS
as 11-20-2024 4:00pm EST
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 100.9M | IPO Year: | 2014 |
| Target Price: | $6.13 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.66 - $3.70 | Next Earning Date: | 11-06-2024 |
| Revenue: | $304,340,000 | Revenue Growth: | 44.19% |
| Revenue Growth (this year): | 3.33% | Revenue Growth (next year): | 16.77% |
Latest Coherus BioSciences Inc. News
CHRS Breaking Stock News: Dive into CHRS Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
14 days ago
Q3 2024 Coherus BioSciences Inc Earnings Call
GuruFocus.com
14 days ago
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
Zacks
14 days ago
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
15 days ago
Coherus BioSciences: Q3 Earnings Snapshot
GlobeNewswire
15 days ago
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
GuruFocus.com
16 days ago
Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to Know Ahead of Earnings
GlobeNewswire
22 days ago
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
GuruFocus.com
a month ago
Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Compare CHRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CHRS Coherus BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.